|
Baseline characteristics of the study population. |
|
| N |
33 |
|
|
|
| Sex (%) |
|
| Male |
51.5 |
| Median Age (years) |
11.7 (7.5–14.2) |
| Median % of Baseline CD4 counts |
23.0 (19.5–32.0) |
| Median % of Baseline CD8 counts (%) |
45.0 (33.5–57.5) |
| Median Baseline VL (HIV-RNA Log copies/ml) |
4.0 (3.4–4.6) |
| Length of ARV therapy (months) |
83.0 (49.0–119.0) |
| Length of PI exposure (months) |
61.0 (38.0–73.0) |
| Length of NRTI exposure (months) |
84.0 (49.0–119.0) |
| Length of NNRTI exposure (months) |
5.0 (0.0–31.0) |
| Median number of previous PI exposure |
2.0 (1–3.0) |
| Median number of NAMs |
3.0 (1.5–4.0) |
| Median number of protease resistance mutations |
5.0 (2.0–6.5) |
|
Results are expressed as median (IQR) (VL: viral load; ARV: antirretroviral treatment; PI: protease inhibitors; NAMs; nucleotide analogue mutations: M41L, D67N, K70R, L210W, T215Y/F y K219Q/E/R/S/N) | |
Larru et al. BMC Infectious Diseases 2007 7:55 doi:10.1186/1471-2334-7-55 |
|